Apiam Animal Health Limited (ASX:AHX) Investor Update
Apiam Animal Health Limited (ASX:AHX) is pleased to provide an update on Apiam Animal Health's year-to-date performance for FY24 up until 31 March 2024 (FY24 YTD).
Apiam Animal Health Limited (ASX:AHX) is pleased to provide an update on Apiam Animal Health's year-to-date performance for FY24 up until 31 March 2024 (FY24 YTD).
Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics is pleased to provide the following update on its business activities for the three months to 31 March 2024.
Apiam Animal Health Limited (ASX:AHX) MD Dr. Chris Richards Speaks with ABN Newswire on Revenue Growth in the Business and the consolidation of acquisitions made by the company over the last two years.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to release a copy of the presentation to be provided by Dr Richard Lipscombe to Jefferies Institutional Clients on 28 March 2024.
Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics, is pleased to announce it has signed a Material Transfer Agreement with the globally-respected University of Oxford to acquire approximately 600 patient plasma samples for its endometriosis study.
Proteomics International Laboratories Ltd (ASX:PIQ) continues to work diligently toward a national launch in the United States of America, of PromarkerD, the Company's innovative predictive test for diabetic kidney disease.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce that is has successfully retained its ISO 13485 certification, an internationally recognised standard for safety and quality management systems in the manufacture of medical devices.